Introduction
============

Radiotherapy is one of the most common and effective treatments for cancer \[[@B1]\]. Radiation damages cancer cells by direct ionization of DNA and by indirect effects caused by reactive oxygen species (ROS) \[[@B2]\]. Ionizing radiation consists of electromagnetic radiations, including X-rays and gamma rays, and particulate radiation such as electrons, protons and neutrons \[[@B2]\]. Exposure to ionizing radiation produces ROS in the tissue environment; including hydroxyl radicals (the most damaging), superoxide anion radicals and other oxidants such as hydrogen peroxide \[[@B2]\]. Although radiotherapy is effective in killing cancer cells, ROS produced in radiotherapy may threaten the integrity and survival of the surrounding normal cells and may cause late side effects of radiotherapy \[[@B1]-[@B3]\]. The administration of radioprotective agents, which are supposed to scavenge radiation-induced radicals and reduce the effects of radiation at an early stage, has been suggested as one approach for prophylaxis of radiation effects in normal tissues \[[@B4],[@B5]\].

Selenium, a trace element, is an essential nutrient of fundamental importance in human biology \[[@B6]\] and as a preventive approach to ROS detoxification, which activates and stimulates the endogenous system \[[@B4],[@B7],[@B8]\]. Some of the most fundamental cellular processes, such as DNA synthesis, depend on the presence of selenium within the catalytic site of thioredoxin reductases (TrxR) \[[@B9],[@B10]\]. A moderate deficiency of selenium has been linked to many conditions, such as an increased risk of cancer, infections and male infertility; a decrease in immune and thyroid function; and several neurological conditions \[[@B6],[@B9]\]. A review paper reported that in prospective studies published in the 1980s and early 1990s involving 8,000 to 11,000 individuals, low selenium status was associated with significantly increased risks of cancer incidence and mortality \[[@B6]\].

A number of mechanisms have been suggested to explain the anti-cancer effects of selenium \[[@B11]\]. Selenium in selenoproteins can reduce oxidative damage and can limit DNA damage, both of which are linked to cancer risk \[[@B11]\]. Other cellular processes and molecular pathways that may be involved in the anti-cancer effects of selenium are the induction of phase II conjugating enzymes that detoxify carcinogens, enhancement of the immune response, an increase in tumor-suppressor protein p53, inactivation of protein kinase C (PKC), alterations in DNA methylation, blockage of the cell cycle to allow DNA repair, induction of apoptosis in cancer cells and inhibition of angiogenesis \[[@B11]\]. In survey studies, selenium has been reported as a complementary alternative medicine (CAM) used in lung and prostate cancer patients undergoing radiotherapy \[[@B12],[@B13]\].

However, there are no guidelines on selenium supplementation in radiotherapy which should consist of inclusion and exclusion criteria for selenium supplementation, applicable cancer types, dose of supplementation, chemical form of selenium, duration of supplementation and the possible side effects of supplementation in radiotherapy. First, however, the benefits and risks of selenium use in radiotherapy should be clarified, as such information is still insufficient. Tabassum et al. \[[@B14]\] summarized the protective effect of selenium against prostate cancer and Fritz et al. \[[@B15]\] reviewed the relationship between selenium and lung cancer, suggesting positive effects of selenium in radiotherapy. Dennert and Horneber reviewed two clinical trials published in 2006 as a Cochrane database systematic review, and the review was revised in 2011 with the addition of one trial \[[@B16]\]. The subjects in the Cochrane database systematic reviews were limited to those included in randomized controlled trials; therefore, only 3 studies were reviewed, yielding no clear evidence that selenium supplements improve the side effects of cancer therapy \[[@B16]\]. In this paper, we summarized the clinical studies on selenium and radiotherapy to provide evidence-based information on the benefits and risks of selenium supplementation to aid in the establishment of guidelines for selenium supplementation in radiotherapy.

Methodology
===========

The flowchart of our literature search is shown in Figure [1](#F1){ref-type="fig"}. Briefly, a PubMed electronic database search using medical subject headings (MeSH) terms and the keywords "selenium", "radiation" and "therapy" in January 2013 yielded 167 articles, 16 of which were clinical studies on selenium and radiotherapy. The detailed keyword search was as follows: "selenium" \[MeSH Terms\] OR "selenium" \[All Fields\]) AND ("radiotherapy" \[Subheading\] OR "radiotherapy" \[All Fields\] OR ("radiation" \[All Fields\] AND "therapy" \[All Fields\]) OR "radiation therapy" \[All Fields\] OR "radiotherapy" \[MeSH Terms\] OR ("radiation" \[All Fields\] AND "therapy" \[All Fields\]) OR "radiation therapy" \[All Fields\]).

![Flowchart of the literature search.](1748-717X-9-125-1){#F1}

Clinical studies on selenium and radiotherapy
---------------------------------------------

Table [1](#T1){ref-type="table"} lists the 16 articles on selenium and radiotherapy in clinical studies. The studies were conducted worldwide, including European, American and Asian countries, between 1987 and 2012. A total of 1303 patients undergoing radiotherapy participated in the studies. Of the 16 articles, 10 articles were observational studies investigating patients' selenium levels before, during and/or after radiotherapy, while the other 6 articles investigated the effects of selenium supplementation studies on cancer patients who underwent radiotherapy. The cancer types investigated were upper gastrointestinal, breast, lung, larynx, head and neck, non-Hodgkin lymphoma, brain, oral, prostate and gynecological cancers.

###### 

Clinical studies on selenium and radiotherapy between 1987 and 2012

   **Study no.**                **Reference**                 **Site of research**                 **Number of patients**                      **Study design**                                                              **Type of cancer/disease**                                                                               **Radiotherapy delivery method**
  --------------- ------------------------------------------ ---------------------- ----------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------
         1                Pothier et al. \[[@B17]\]                   USA                                  n = 71                          Observation of Se levels                                                        Upper gastrointestinal cancer                                                                                        Not mentioned
         2                 Antila et al. \[[@B18]\]                 Finland                                n = 24                          Observation of Se levels                                                                Breast cancer                                                                               Energy photons followed by 6--12 MeV electrons
         3               Piccinini et al. \[[@B19]\]                 Italy                                 n = 66                          Observation of Se levels                                                 Breast cancer (n = 38), lung cancer (n = 28)                                                                                Not mentioned
         4          Rostkowska-Nadolska et al. \[[@B20]\]            Poland                                n = 78                          Observation of Se levels                                                           carcinoma of the larynx                                                                                           X-Ray therapy
         5                 Yadav et al. \[[@B21]\]                   India                                 n = 30                          Observation of Se levels                                                             Head and neck cancer                                                                                            Not mentioned
         6                  Last et al. \[[@B22]\]                     UK                                  n = 100                         Observation of Se levels                                                            Non-Hodgkin's lymphoma                                                                                           Not mentioned
         7               Fraunholz et al. \[[@B23]\]                Germany                                n = 224                         Observation of Se levels   Breast cancer (n = 94); cervical csncer (n = 25); head and neck cancer (n = 23); lung cancer (n = 19); prostate (n = 13); other (n = 50)           6-MV and/or 25-MV photons generated by a linear accelerator
         8                 Franca et al. \[[@B24]\]                  Brazil                                n = 209                         Observation of Se levels                                                                Breast cancer                                                                                                Not mentioned
         9                Zeng YC et al. \[[@B25]\]                  China                                 n = 95                          Observation of Se levels                                               Non-small cell lung cancer with brain metastases                                                                     6MV external beam radiotherapy
        10                Eroglu C et al. \[[@B26]\]                 Turkey                                n = 47                          Observation of Se levels                                                             Head and neck cancer                                                                                            Not mentioned
        11                   Pakdaman, \[[@B27]\]                   Germany                                n = 32                             Se supplementation                                                                    Brain tumor                                                                                                 Not mentioned
        12         Kiremidjian-Schumacher et al. \[[@B28]\]           USA               n = 33 supplemented (n = 17) placebo (n = 16)         Se supplementation                                                                Head and neck cancer                                                                                            Not mentioned
        13                 Micke et al. \[[@B29]\]                  Germany                                n = 48                             Se supplementation                                                                Secondary lymphedema                                                                 a linear accelerator with 6-MeV photons or a ^60^Co treatment unit
        14                 Elango et al. \[[@B30]\]                  India                                 n = 126                            Se supplementation                                                                    Oral cancer                                                                  a tele-cobalt beam (Theratron-780-^60^Co; phoenix-^60^Co; Gammatron-^60^Co)
        15                 Muecke et al. \[[@B31]\]                 Germany          n = 81 supplemented (n = 39) control group (n = 42)      Se supplementation                                                 Cervical cancer (n = 11); uterine cancer (n = 70)                                                                     6- to 18-MV linear accelerator
        16                Buntzel et al. \[[@B32]\]                 Germany                                n = 39                             Se supplementation                                                                Head and neck cancer                                                                                            Not mentioned
                                                                                                        Total = 1303                                                                                                                                                                                                                                   

Among the 16 articles, only 7 articles mentioned the types of radiotherapy delivered to the patients, and in most cases, electromagnetic radiations was used.

### Observational studies

Table [2](#T2){ref-type="table"} presents the observational studies investigating the selenium levels in patients who underwent radiotherapy without selenium supplementation. In addition to the 10 observational studies, 2 studies assessed selenium levels in patients who did not received selenium supplementation, who served as a placebo group and control group in the selenium supplementation studies. Thus, a total of 12 studies measured the selenium levels in patients who underwent radiotherapy without selenium supplementation.

###### 

Observational studies investigating the selenium levels in patients who underwent radiotherapy without selenium supplementation

       **Study no.**                     **Reference**                         **Sample**            **Measurement method**   **Mean selenium levels (μg/l)**                                                                
  ------------------------ ------------------------------------------ ----------------------------- ------------------------ --------------------------------- ------------------- ------------ ------------------ --------- ------------
             1                     Pothier et al. \[[@B17]\]                     Plasma                       AAS                 61.8 (at stable stage)         1 week (n = 5)     34.3 **↓**          \-            \-          \-
             2                      Antila et al. \[[@B18]\]                      Serum                       AAS                         130.7\*               Middle of therapy    124.4\*         128.3\*        2 weeks    126.7\*
          2 months                          121.2\*                                                                                                                                                                          
             3                    Piccinini et al. \[[@B19]\]                    Plasma               Fluorometric method          Breast cancer: 71.81                \-               \-              \-            \-          \-
     Lung cancer:69.59                                                                                                                                                                                                       
             4               Rostkowska-Nadolska et al. \[[@B20]\]                Serum                       AAS                        253.8\*\*                     \-               \-              \-          6 weeks   267.5\*\*
             5                      Yadav et al. \[[@B21]\]                       Serum                       AAS                          62.7                        \-               \-             61.0         1 year    Cured:91.5
   Residual disease: 61.8                                                                                                                                                                                                    
             6                       Last et al. \[[@B22]\]                       Serum                      ICP-MS                       72.44\*                      \-               \-              \-            \-          \-
             7                    Fraunholz et al. \[[@B23]\]                  Whole blood                    AAS                          75.64                       \-               \-            75.88         6 weeks     81.28
             8                      Franca et al. \[[@B24]\]                     Plasma                       AAS                     ≤60 years:101.8                  \-               \-       ≤60 years: 58.1↓     \-          \-
      \>60 years:65.2                  \>60 years: 33.7↓                                                                                                                                                                     
             9                     Zeng YC et al. \[[@B25]\]                   Whole blood                    AAS                          90.4                        \-               \-            56.3↓           \-          -'
             10                    Eroglu C et al. \[[@B26]\]                     Serum                      ICP-MS                        58.09                       \-               \-            56.34           \-          \-
             12             Kiremidjian-Schumacher et al. \[[@B28]\]     Plasma (placebo group)       Graphite-furnace AAS                 94.38                       \-               \-       8th weeks: 91.8    8 weeks     89.92
             15                     Muecke et al. \[[@B31]\]           Whole blood (control group)            AAS                          63.2                  50% of therapy        67.3            61.4         6 weeks       69

↓ = significant decrease.

\*1 μmol/l = 1 μg/l x 0.0127 \[[@B33]\].

\*\*1 ppm = 1,000 μg/l.

#### Selenium levels

Selenium levels were determined in the plasma, serum or whole blood using atomic absorption spectrometry (AAS) in 9 studies, inductively coupled plasma mass spectrometry (ICP-MS) in 2 studies and a fluorometric method in 1 study. The measurements were performed before radiotherapy, during radiotherapy, at the end of therapy and at specific time points (2 weeks, 6 weeks, 8 weeks or 1 year) after therapy completion.

#### Effect of radiotherapy on selenium levels

The results of selenium levels in patients who underwent radiotherapy without supplementation demonstrated that selenium levels had a tendency to decrease after radiotherapy. In 7 studies (study No. 2, 4, 5, 7, 10, 12, and 15), the selenium levels were not significantly different before and after therapy, but in 3 studies (study No. 1, 8, and 9), the selenium levels after therapy were significantly lower than those before therapy.

### Effect of selenium supplementation on selenium levels

Table [3](#T3){ref-type="table"} shows the selenium levels in the patients who underwent radiotherapy with selenium supplementation. The selenium levels in patients who received selenium supplementation had a tendency to increase after radiotherapy. However, the selenium levels decreased again at 8 weeks (study No.12) and 6 weeks (study No.15) after the completion of radiotherapy without selenium supplementation.

###### 

Selenium levels in patients who underwent radiotherapy with selenium supplementation

   **Study no.**                **Reference**                  **Sample**     **Measurement method**   **Mean selenium levels (μg/L)**                                                                                              
  --------------- ------------------------------------------ --------------- ------------------------ --------------------------------- ---------------- ----------- ------------------------- ------------------------------------ -------
         9                   Pakdaman, \[[@B27]\]             Not mentioned       Not mentioned                      63                        \-            \-              120 **↑**                          \-                    \-
        12         Kiremidjian-Schumacher et al. \[[@B28]\]      Plasma        Graphite-furnace AAS                 91.29                      \-            \-       8th weeks: 105.29 **↑**   8 weeks (without supplemen-tation)   88.73
        15                 Muecke et al. \[[@B31]\]            Whole blood             AAS                          65.3                 50% of therapy   93.2**↑**         90.9 **↑**          6 weeks (without supplemen-tation)   73.2

↑ = increase.

### Selenium supplementation studies

Table [4](#T4){ref-type="table"} provides a summary of selenium supplementation studies. The selenium supplementation studies in patients who underwent radiotherapy were conducted from 1998 to 2010. Different types of studies were conducted, including a randomized double-blind placebo-controlled study (study No. 12), a multicenter phase 3 trial (study No. 15), and a randomized phase 2 study (study No.16).

###### 

Selenium supplementation studies in patients who underwent radiotherapy

   **Study no.**                **Reference**                            **Type of cancer/disease**                             **Type of study**                   **Form of Se used for supplementation**       **Dose (μg)**                 **Administration**                                   **Items observed/measured**                                                                   **Result**
  --------------- ------------------------------------------ -------------------------------------------------- -------------------------------------------------- ----------------------------------------- ----------------------- ----------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------
        11                   Pakdaman, \[[@B27]\]                               Brain tumor                                       Not mentioned                                 Sodium selenite               1000/day (4--8 weeks)       Infusion (during radiotherapy)        Mineral elements, Se and other blood parameters (AST, ALT, γ-GTP, ESR)   A significant diminution of symptoms of intracranial pressure was achieved in 76% of patients.
        12         Kiremidjian-Schumacher et al. \[[@B28]\]                 Head and neck cancer                 Randomized double-blind placebo-controlled study               Sodium selenite                 200/day (8 weeks)           Oral (during radiotherapy)                               Se in plasma, CTL, MLR, PHA                                           Significantly enhanced cell-mediated immune responsiveness
        13                 Micke et al. \[[@B29]\]                          Secondary Lymphedema                                  Not mentioned                                 Sodium selenite               500/day (4--6 weeks)    Oral (4 or10 months after radiotherapy)                Foldi and Miller scoring and quality of life                       Foldi and Miller score: more than 78% showed an improvement of one stage or more
        14                 Elango et al. \[[@B30]\]                             Oral cancer                                       Not mentioned                                 Sodium selenite                400/day (6 months)           Oral (during radiotherapy)           Plasma Se, enzymatic (GPx and others) and non-enzymatic antioxidants               Supplementation increased the enzymatic and non enzymatic defense systems
        15                 Muecke et al. \[[@B31]\]           Cervical cancer (n = 11); Uterin cancer (n = 70)              Multicenter, phase 3 trial                          Sodium selenite                  500 or 300/day             Oral (during radiotherapy)                                      Whole blood Se                               Statistically significant in reducing the number of episode and severity of RT-induced diarrhea
        16                Buntzel et al. \[[@B32]\]                        Head and neck (n = 39)                           Randomized phase II study                           Sodium selenite                  500 or 300/day             Oral (during radiotherapy)                                  Side effect evaluation                                              Reduced the development of dysphagia due to radiotherapy

#### Therapeutic form of selenium, dose and administration

All of the studies of selenium supplementation in patients who underwent radiotherapy used sodium selenite as the form of selenium for supplementation. Sodium selenite was administered orally in most studies (study No. 12--16) and in physiological saline in another report. The dose of supplementation by oral administration ranged from 200 to 500 μg daily, or 1,000 μg daily by infusion in physiological saline.

#### Parameters observed or measured

To assess the effectiveness of selenium supplementation in radiotherapy, the parameters measured or observed in the studies were selenium levels in the serum, plasma or whole blood; mineral elements in the blood and other blood parameters (aspartate amino transferase (AST), alanine amino transferase (ALT), gamma glutamyl transpeptidase (γ-GTP) and erythrocyte sedimentation rate (ESR)) \[[@B27]\]; immune function \[[@B28]\]; quality of life \[[@B29]\]; enzymatic and non-enzymatic antioxidants \[[@B30]\]; and side effects \[[@B31],[@B32]\].

#### Effects of selenium supplementation on therapy

Most of the studies revealed positive effects of selenium supplementation on the general condition of the patients and their quality of life. The effects of supplementation were different depending on cancer type. No reduction in effectiveness of radiotherapy \[[@B31]\] and no selenium toxicities or complications were reported in any of the supplementation studies.

Pakdaman (study No.11) reported that treatment with sodium selenite in patients with brain tumors was well tolerated by all patients and increased blood selenium levels \[[@B27]\]. A significant diminution of symptoms of intracranial pressure was achieved in 76% of patients after sodium selenite treatment \[[@B27]\].

In the study by Kiremidjian-Schumacher et al. (study No. 12), sodium selenite treatment was shown to significantly enhance cell-mediated immune responsiveness in head and neck cancer patients \[[@B28]\]. This outcome related to the ability of selenium to enhance the expression of both the α- (p55) and β- (p70/75) subunits of the interleukin-2 receptor (IL2-R), which resulted in a greater number of high-affinity IL2-R/cells and enhanced proliferation and differentiation in cytotoxic effector cells \[[@B28],[@B34],[@B35]\].

Micke et al. (study No. 13) demonstrated, using the visual analogue scale, that the self-assessment of the quality of life of patients suffering from head and neck cancer with lymphedema significantly improved after selenium supplementation \[[@B29]\].

Elango et al. (study No. 14) found that supplementation with selenium in oral cancer patients for 6 months may help to increase the enzymatic (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), Glutathione reductase (GRx), Glucose-6-phosphate dehydrogenase (G6PDH)) and non-enzymatic (glutathione (GSH), vitamin E, vitamin C, vitamin A and ceruloplasmin) defense systems. The mechanism of the increase in the activity of the enzymatic defense system is due to increased GPx synthesis as a result of the enhanced *de novo* synthesis of this enzyme in the erythroid precursors of red blood cells \[[@B30]\].

Muecke et al. (study No. 15) reported that selenium supplementation in cervical and uterine cancer patients yielded significant prevention of diarrhea and thus improved the quality of life \[[@B31]\]. The increased activity of the protective intestinal GPx isoenzymes may be responsible for these effects due to the enhanced neutralization of radiation-induced hydroperoxides and free radicals in the small intestinal mucosa included in the radiation volume \[[@B31]\].

In the study by Büntzel et al. (study No.16) selenium supplementation reduced the radiation-associated side-effects of dysphagia developments in patients with head and neck cancer patients \[[@B32]\].

### Parameters used to assess the effect of radiotherapy on selenium status

We found that the plasma, serum or whole blood selenium levels were common parameters used to assess the effect of radiotherapy on selenium status and the effectiveness of selenium supplementation. Selenium levels had a tendency to decrease after radiotherapy and to increase with selenium supplementation. The mechanism of this decrease is still unclear \[[@B24],[@B25]\]. Pothier et al. suggested that poor dietary intake due to anorexia, nausea, and obstruction, compounded by selenium loss from vomiting, diarrhea, and malabsorption, probably played a role in the decrease \[[@B17]\]. Radiotherapy and chemotherapy, combined with the suboptimal nutrition of cancer patients, may further aggravate the selenium deficiency \[[@B24],[@B31]\]. Muecke et al. highlighted that patients with higher blood selenium levels had a better radiation tolerance, without any effect on the survival data \[[@B31]\]. Therefore, Muecke et al. and Franca et al. strongly recommended that physicians take the selenium status into account before prescribing any anticancer therapy to their patients or consider additional supplementation before therapy when the current selenium status appears insufficient \[[@B24],[@B31]\].

### Sodium selenite supplementation

In the studies reviewed, sodium selenite was the only form of selenium used for supplementation. In nature, selenium exists in many forms. The most well studied forms are selenomethionine (SeMet), sodium selenite, selenium methylselenocysteine, 1,4,-phenylenebis (methylene) selenocyanate (p-XSC), and methylseleninic acid (MSA) \[[@B15]\]. Selenomethionine and selenocysteine (SeCys) are found predominantly in foods such as bread, cereals, nuts, meat, fish, and other seafood \[[@B36]\]. In human antioxidant systems, selenium participates in the form of SeCys incorporated into the various selenoproteins \[[@B11],[@B15]\]. There are at least 25 known selenoproteins, including GPx, TrxR, iodothyroninedeiodinase, and the selenoproteins P, W and R \[[@B37]\]. The most abundant selenoproteins in the blood are selenoprotein P, which accounts for approximately 50% of plasma selenium \[[@B36],[@B38],[@B39]\], and GPx, which accounts for 10--30% of plasma selenium \[[@B36],[@B39]\].

Sodium selenite, an inorganic form of selenium, was used for supplementation because it can primarily improve the expression of selenoproteins after specific incorporation as SeCys \[[@B31]\]. Sodium selenite also has high biological activity and availability in the body \[[@B28]\] and is known to easily pass the blood--brain barrier \[[@B27]\]. It does not raise the concentrations of nonspecific selenium-containing proteins (e.g., selenium-albumin), which is in contrast to other widely used organic selenium supplements (e.g., selenomethionine) \[[@B31]\].

### Selenium toxicity

The Food and Nutrition Board, Institute of Medicine, suggested a recommended dietary allowance (RDA) of selenium for both men and women of 55 μg (0.7 μmol)/day \[[@B40]\]. The tolerable upper intake level (UL) of selenium in adults is set at 400 μg (5.1 μmol)/day based on the adverse effect of selenosis \[[@B40]\]. The results of our review of supplementation studies revealed that selenium supplementation doses ranging from 200--500 μg/day by oral administration was well tolerated by all patients, and no toxicities were reported. Selenium supplementation increased the blood selenium level, improved the general condition of patients, improved quality of life and prevented or reduced the side effects of radiotherapy. Muecke et al. \[[@B31]\] also implied that supplementation with selenium neither interferes with the biological effects of ionizing radiation nor protects tumor cells.

The Nutritional Prevention of Cancer (NPC) trial reported that selenium supplementation in subjects, with histories of non-melanoma skin cancers significantly decreased the incidence of lung cancer in patients with low baseline selenium concentrations, but supplementation did not significantly decrease this incidence among individuals in the overall population \[[@B41]\]. Therefore, selenium supplementation may have benefits if the selenium is administered to patients with low selenium levels.

High-dose selenium and long-term supplementation may be ineffective and unsafe because selenium can be toxic at high concentrations. The NPC trial also reported an association between long-term selenium supplementation and an increased risk of diabetes \[[@B42]\]. A review paper in 2006 \[[@B43]\] revealed that serum selenium levels ranging from 400--30,000 μg/l were associated with acute toxicity and that levels ranging from 500--1,400 μg/l were associated with chronic toxicity (mean normal serum selenium level is 125 μg/l \[[@B44]\]).

Another high-dose selenium case consisting of the use of a liquid dietary supplement containing 200 times the labeled concentration of selenium was reported in the United States \[[@B44]\]. Of the 201 cases identified in 10 states, 1 person was hospitalized. The median estimated dose of selenium consumed was 41,749 μg/day. The frequently reported symptoms included diarrhea (78%), fatigue (75%), hair loss (72%), joint pain (70%), nail discoloration (61%) and nausea (58%). The symptoms persisting 90 days or longer included fingernail discoloration and loss (52%), fatigue (35%), and hair loss (29%) \[[@B44]\].

Conclusion
==========

This paper summarized 16 clinical studies on selenium and radiotherapy conducted from 1987 to 2012. The studies included 1303 cancer patients. To assess the selenium status in patients before and after radiotherapy, the plasma, serum or whole blood selenium level was a common parameter used to assess the effect of radiotherapy on selenium status and the effectiveness of selenium supplementation. Selenium supplementation increased the blood selenium level, improved the general condition of patients, improved quality of life, prevented or reduced the side effects of radiotherapy and did not reduce the effectiveness of radiotherapy or cause any toxicity.

The results of our summary suggest that selenium supplementation in the form of sodium selenite at doses ranging from 200--500 μg daily by oral administration may offer benefits for head and neck cancer; head and neck cancer with lymphedema; and oral, cervical and uterine cancer patients who undergo radiotherapy and have low selenium levels. In the future, further research and additional evidence of the benefits of selenium supplementation in patients during radiotherapy are required to clarify optimal dosing strategies in specific types of cancer and the associated risks, to ensure therapeutic efficacy before it can be recommended for broad clinical use.
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